Vaccines,
Год журнала:
2024,
Номер
13(1), С. 30 - 30
Опубликована: Дек. 31, 2024
The
COVID-19
pandemic,
caused
by
the
Severe
Acute
Respiratory
Syndrome
Coronavirus
2
(SARS-CoV-2),
is
in
its
sixth
year
and
being
maintained
inability
of
current
spike-alone-based
vaccines
to
prevent
transmission
leading
continuous
emergence
variants
sub-variants
concern
(VOCs).
This
underscores
critical
need
for
next-generation
broad-spectrum
pan-Coronavirus
(pan-CoV
vaccine)
break
this
cycle
end
pandemic.
development
a
pan-CoV
vaccine
offering
protection
against
wide
array
VOCs
requires
two
key
elements:
(1)
identifying
protective
antigens
that
are
highly
conserved
between
passed,
current,
future
VOCs;
(2)
developing
safe
efficient
antigen
delivery
system
induction
broad-based
long-lasting
B-
T-cell
immunity.
review
will
present
state
platforms
involving
multifaceted
approach,
including
bioinformatics,
molecular
structural
biology,
immunology,
advanced
computational
methods;
discuss
challenges
facing
effective
platforms;
(3)
highlight
potential
nucleoside-modified
mRNA
encapsulated
lipid
nanoparticles
(LNP)
as
platform
well
suited
needs
vaccine,
such
ability
induce
immunity
amenable
large-scale
manufacturing
safely
provide
durable
threats.
Frontiers in Cellular and Infection Microbiology,
Год журнала:
2025,
Номер
14
Опубликована: Янв. 20, 2025
Messenger
RNA
(mRNA)
vaccines
offer
an
adaptable
and
scalable
platform
for
cancer
immunotherapy,
requiring
optimal
design
to
elicit
a
robust
targeted
immune
response.
Recent
advancements
in
bioinformatics
artificial
intelligence
(AI)
have
significantly
enhanced
the
design,
prediction,
optimization
of
mRNA
vaccines.
This
paper
reviews
technologies
that
streamline
vaccine
development,
from
genomic
sequencing
lipid
nanoparticle
(LNP)
formulation.
We
discuss
how
accurate
predictions
neoantigen
structures
guide
sequences
effectively
target
cells.
Furthermore,
we
examine
AI-driven
approaches
optimize
mRNA-LNP
formulations,
enhancing
delivery
stability.
These
technological
innovations
not
only
improve
but
also
enhance
pharmacokinetics
pharmacodynamics,
offering
promising
avenues
personalized
immunotherapy.
Abstract
Long
COVID
(also
known
as
post-acute
sequelae
of
SARS-CoV-2
infection
[PASC]
or
post-COVID
syndrome)
is
characterized
by
persistent
symptoms
that
extend
beyond
the
acute
phase
infection,
affecting
approximately
10%
to
over
30%
those
infected.
It
presents
a
significant
clinical
challenge,
notably
due
pronounced
neurocognitive
such
brain
fog.
The
mechanisms
underlying
these
effects
are
multifactorial,
with
mounting
evidence
pointing
central
role
cerebromicrovascular
dysfunction.
This
review
investigates
key
pathophysiological
contributing
cerebrovascular
dysfunction
in
long
and
their
impacts
on
health.
We
discuss
how
endothelial
tropism
direct
vascular
trigger
dysfunction,
impaired
neurovascular
coupling,
blood–brain
barrier
disruption,
resulting
compromised
cerebral
perfusion.
Furthermore,
appears
induce
mitochondrial
enhancing
oxidative
stress
inflammation
within
cells.
Autoantibody
formation
following
also
potentially
exacerbates
injury,
chronic
ongoing
compromise.
These
factors
collectively
contribute
emergence
white
matter
hyperintensities,
promote
amyloid
pathology,
may
accelerate
neurodegenerative
processes,
including
Alzheimer’s
disease.
emphasizes
critical
advanced
imaging
techniques
assessing
health
need
for
targeted
interventions
address
complications.
A
deeper
understanding
essential
advance
treatments
mitigate
its
long-term
consequences.
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2024,
Номер
12
Опубликована: Март 28, 2024
Codon
optimization
has
evolved
to
enhance
protein
expression
efficiency
by
exploiting
the
genetic
code's
redundancy,
allowing
for
multiple
codon
options
a
single
amino
acid.
Initially
observed
in
Vaccines,
Год журнала:
2024,
Номер
12(10), С. 1148 - 1148
Опубликована: Окт. 8, 2024
The
advent
of
lipid
nanoparticles
(LNPs)
as
a
delivery
platform
for
mRNA
therapeutics
has
revolutionized
the
biomedical
field,
particularly
in
treating
infectious
diseases,
cancer,
genetic
disorders,
and
metabolic
diseases.
Recent
Advances
Therapeutic
LNPs:
LNPs,
composed
ionizable
lipids,
phospholipids,
cholesterol,
polyethylene
glycol
(PEG)
facilitate
efficient
cellular
uptake
cytosolic
release
while
mitigating
degradation
by
nucleases.
However,
synthetic
entities,
LNPs
face
challenges
that
alter
their
therapeutic
efficacy
safety
concerns.
Toxicity/Reactogenicity/Immunogenicity:
This
review
provides
comprehensive
overview
latest
advancements
LNP
research,
focusing
on
preclinical
assessments
encompassing
toxicity,
reactogenicity,
immunogenicity.
Summary
Outlook:
Additionally,
it
outlines
potential
strategies
addressing
these
offers
insights
into
future
research
directions
enhancing
application
therapeutics.
Clinical Pharmacology & Therapeutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 14, 2025
The
utilization
of
lipid
nanoparticles
(LNP)
for
encapsulating
mRNA
has
revolutionized
the
field
therapeutics,
enabling
rapid
development
COVID‐19
vaccines
and
cancer
vaccines.
However,
clinical
mRNA‐LNP
therapeutics
faces
numerous
challenges
due
to
their
complex
mechanisms
action
limited
experience.
To
overcome
these
hurdles,
Model‐Informed
Drug
Development
(MIDD)
emerges
as
a
valuable
tool
that
can
be
applied
facilitating
evaluation
safety
efficacy
through
integration
data
from
all
stages
into
appropriate
modeling
simulation
techniques.
In
this
review,
we
provide
an
overview
current
MIDD
applications
in
using
vivo
data.
A
variety
methods
are
reviewed,
including
quantitative
system
pharmacology
(QSP),
physiologically
based
pharmacokinetics
(PBPK),
mechanistic
pharmacokinetics/pharmacodynamics
(PK/PD),
population
PK/PD,
model‐based
meta‐analysis
(MBMA).
Additionally,
compare
differences
between
mRNA‐based
small
interfering
RNA,
adeno‐associated
virus‐based
gene
therapies
terms
pharmacology,
discuss
potential
mutual
sharing
knowledge
therapeutics.
Furthermore,
highlight
promising
future
opportunities
applying
approaches
drugs.
By
emphasizing
importance
throughout
development,
review
aims
encourage
stakeholders
recognize
value
its
enhance
Expert Review of Clinical Immunology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 18, 2025
Glioma
is
the
most
common
primary
brain
tumor,
with
glioblastoma
being
lethal
type
due
to
its
heterogeneous
and
invasive
nature
of
cancer.
Current
therapies
have
low
curative
success
are
limited
surgery,
radiotherapy,
chemotherapy.
More
than
50%
patients
become
resistant
chemotherapy,
tumor
recurrence
occurs
in
following
an
initial
course
therapy.
Therefore,
developing
novel,
effective
strategies
for
glioma
treatment
essential.
Cancer
vaccines
novel
that
demonstrate
advantages
over
conventional
methods
and,
therefore,
may
be
promising
options
treating
glioma.
This
article
provided
a
critical
review
pre-clinical
clinical
studies
explored
appropriate
antigen
candidates
mRNA
discussed
their
application
patients.
Medline
database,
PubMed,
ClinicalTrials.gov
were
searched
vaccine
published
before
2025
using
related
keywords.
because
they
efficient,
cost-beneficial,
lower
side
effects
other
types
such
as
peptide
or
DNA-based
vaccines.
Medicina,
Год журнала:
2024,
Номер
60(8), С. 1343 - 1343
Опубликована: Авг. 19, 2024
:
An
unexpected
batch-dependent
safety
signal
for
the
BNT162b2
mRNA
COVID-19
vaccine
was
recently
identified
in
a
nationwide
study
from
Denmark,
but
generalizability
of
this
finding
is
unknown.
Therefore,
we
compared
rates
suspected
adverse
events
(SAEs)
reported
to
national
authorities
Denmark
and
Sweden.
International Journal of Risk & Safety in Medicine,
Год журнала:
2024,
Номер
35(4), С. 317 - 333
Опубликована: Ноя. 1, 2024
Background:
Of
many
pharmaceutical
products
launched
for
the
benefit
of
humanity,
a
significant
number
have
had
to
be
recalled
from
marketplace
due
adverse
events.
A
systematic
review
found
market
recalls
462
between
1953
and
2013.
In
our
current
remarkable
period
medical
history,
excess
mortality
figures
are
high
in
countries.
Yet
these
statistics
receive
limited
attention,
often
ignored
or
dismissed
by
mainstream
news
outlets.
This
may
include
effects
caused
novel
agents
that
use
gene-code
technology.
Objective:
To
examine
key
product
withdrawals
derive
lessons
inform
gene-based
COVID-19
vaccines.
Methods:
Selective
narrative
historical
comparative
issues
with
recent
Results:
Parallels
past
drug
vaccines
distortion
clinical
trial
data,
critical
event
data
absent
high-impact
journal
publications.
Delayed
regulatory
action
on
pharmacovigilance
trigger
withdrawal
occurred
Vioxx
(rofecoxib)
is
apparent
Conclusion:
Public
health
requires
access
raw
improved
transparency
corporations
heightened,
active
worldwide.
